Landmark Phase 3 Study of Xarelto Plus Aspirin Shows Significant Benefit in Patients with Symptomatic PAD after Lower-Extremity Revascularization - PharmaLive
[unable to retrieve full-text content] Emerging biomarkers and frontier therapies: unveiling the role of endothelial dysfunction in cerebral small vessel disease Frontiers
Comments
Post a Comment